LML338K • October 2021 • US$6,850
There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes. More than three dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Several targeted therapeutics indications, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Their success has attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of Leukemias and related blood cancers. This report examines two dozen targeted therapeutics leukemia indications including therapeutic drugs targeting leukemias, and their mechanisms of action.
Target Oncology Hematology Cancers – What You Will Learn
• What is the market share of approved hematology cancer therapeutics?
• What is the global supply picture for targeted hematology cancer therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the hematology cancer market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation hematology cancer therapeutics?
Targeted Oncology Hematology Cancers – Summary of Contents
Targeted Oncology Therapeutics
The Recombinant Drug Ecosystem
mAbs and Targeted Oncology Therapeutics
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Childhood Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Biological Drugs for Hematology Cancers
Monoclonal Antibodies (Twelve Therapeutic Products)
Tyrosine Kinase Inhibitors
ALL with Philadelphia chromosome (Ph+ ALL)
FDA Approved TKIs (Six Therapeutic Products)
Chimeric Antigen Receptor-T (CAR-T) (Five Products)
The Therapeutic Market Landscape
Drugs in Development – The Clinical Trial Picture
FDA-Approved Targeted Oncology
Therapeutics for Hematology Cancers